GSK said that Tafinlar, also known as dabrafenib,
was designated an FDA breakthrough therapy on Monday following
interim results from an ongoing Phase II study.
Tafinlar is already approved for melanoma, the deadliest form of
(Reporting by Sarah Young; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.